Samuel Olusegun Adeosun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Samuel Olusegun Adeosun has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Afua B. Faibille
Fred Wilson School of Pharmacy, High Point University One University Parkway, High Point, NC, 27268, USA
1 shared publicationAisha N. Qadir
Fred Wilson School of Pharmacy, High Point University One University Parkway, High Point, NC, 27268, USA
1 shared publicationAyonna M. Hollowell
One University Parkway, High Point University, Fred Wilson School of Pharmacy, Department of Clinical Sciences, High Point, NC, USA
1 shared publicationFaith L. Lemmons
1 shared publicationJacob K. Walters
Fred Wilson School of Pharmacy, High Point University, One University Parkway, High Point, NC, 27268, United States
1 shared publicationJerotich T. Mutwol
Fred Wilson School of Pharmacy, High Point University One University Parkway, High Point, NC, 27268, USA
1 shared publication
Latest Publications
- 21 August 2026
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 90 (11)
Development of a Data-Driven, Noninflationary Author-Credit Allocation Model in Multiauthor Publications in Pharmacy Practice
- 21 August 2026
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 90 (11)
Development of a Data-Driven, Noninflationary Author-Credit Allocation Model in Multiauthor Publications in Pharmacy Practice
- 23 August 2025
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 22 (1) , 107-115
Development and characterization of a theory- and data-driven core journals list in pharmacy practice
- 23 August 2025
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 22 (1) , 107-115
Development and characterization of a theory- and data-driven core journals list in pharmacy practice
- 26 March 2025
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 89 (5) , 101398
Impact of COVID-19 on Scholarly Outcomes of Pharmacy Practice Faculty by Gender and Academic Rank
- 26 March 2025
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 89 (5) , 101398
Impact of COVID-19 on Scholarly Outcomes of Pharmacy Practice Faculty by Gender and Academic Rank
- Open Access
AuthormetriX: Automated Calculation of Individual Authors’ Non-Inflationary Credit-Allocation Schemas’ and Collaboration Metrics from a Scopus Corpus
Background: Publication count is the currency in academia, but the most widely used whole count method is considered unfair and inflationary. Several non-inflationary author credit-allocation schemas (NIACAS) have been proposed, but none is widely adopted in practice (e.g., in evaluating faculty scholarly productivity) or in bibliometric research. This low adoption and implementation rate may be due to the complexity in operationalizing the schemas. Aim: To develop an application that automates the calculation of individual authors’ scholarly output metrics based on multiple NIACAS. Method: Published formulas of NIACAS were written as Python functions wrapped in a Streamlit user interface that takes . csv files of the relevant corpus, and a list of author’s Scopus IDs as inputs. The functions calculate the authors’ output metrics based on NIACAS including first- and last-author straight counts, arithmetic, golden share, and multiple variations of fractional, geometric, and harmonic schemas. Collaboration metrics are also calculated. Secondary features include modelers for author counts and schemas. In a use-case, absolute rank displacement (ARD) and actual contribution proportions (ACP) were compared between highly cited clinical medicine researchers and high h -index pharmacy practice faculty populations. Results: AuthormetriX accurately calculates individual authors’ aggregate scholarly output based on 14 NIACAS, from the file inputs. There were schema and population differences in ACP, but only schema differences in ARD within the populations studied. Conclusions: AuthormetriX simplifies the implementation of non-inflationary author credit-allocation schemas and will facilitate their broader adoption in practice and bibliometric research. AuthormetriX is freely available at https://sadeosun-a-uthormetrix-v1.streamlit.app/ .
Open AccessAuthormetriX: Automated Calculation of Individual Authors’ Non-Inflationary Credit-Allocation Schemas’ and Collaboration Metrics from a Scopus Corpus
Background: Publication count is the currency in academia, but the most widely used whole count method is considered unfair and inflationary. Several non-inflationary author credit-allocation schemas (NIACAS) have been proposed, but none is widely adopted in practice (e.g., in evaluating faculty scholarly productivity) or in bibliometric research. This low adoption and implementation rate may be due to the complexity in operationalizing the schemas. Aim: To develop an application that automates the calculation of individual authors’ scholarly output metrics based on multiple NIACAS. Method: Published formulas of NIACAS were written as Python functions wrapped in a Streamlit user interface that takes . csv files of the relevant corpus, and a list of author’s Scopus IDs as inputs. The functions calculate the authors’ output metrics based on NIACAS including first- and last-author straight counts, arithmetic, golden share, and multiple variations of fractional, geometric, and harmonic schemas. Collaboration metrics are also calculated. Secondary features include modelers for author counts and schemas. In a use-case, absolute rank displacement (ARD) and actual contribution proportions (ACP) were compared between highly cited clinical medicine researchers and high h -index pharmacy practice faculty populations. Results: AuthormetriX accurately calculates individual authors’ aggregate scholarly output based on 14 NIACAS, from the file inputs. There were schema and population differences in ACP, but only schema differences in ARD within the populations studied. Conclusions: AuthormetriX simplifies the implementation of non-inflationary author credit-allocation schemas and will facilitate their broader adoption in practice and bibliometric research. AuthormetriX is freely available at https://sadeosun-a-uthormetrix-v1.streamlit.app/ .
- Open Access
- 26 November 2024
- Published by University of Minnesota in INNOVATIONS in pharmacy
- Vol. 15 (4) , 5
Scopus Indexing Delays of Articles Published in Major Pharmacy Practice Journals
Inspiring Inquiry and Improvement in Pharmacy Practice, Education, and Policy A quarterly publication featuring case studies, clinical experiences, commentaries, idea papers, original research, and review articles that focus on the leading edge, novel ideas for improving, modernizing, and advancing pharmacy practice, education, and policy. INNOVATIONS in pharmacy is an academic, peer reviewed, open-access journal. Sponsored by U of MN College of Pharmacy Inspiring Inquiry and Improvement in Pharmacy Practice, Education, and Policy. A quarterly publication featuring case studies, clinical experiences, commentaries, idea papers, original research, review articles, and student projects that focus on leading edge, novel ideas for improving, modernizing, and advancing pharmacy practice, education, and policy. INNOVATIONS in pharmacy.
- 26 November 2024
- Published by University of Minnesota in INNOVATIONS in pharmacy
- Vol. 15 (4) , 5
Open AccessScopus Indexing Delays of Articles Published in Major Pharmacy Practice Journals
Inspiring Inquiry and Improvement in Pharmacy Practice, Education, and Policy A quarterly publication featuring case studies, clinical experiences, commentaries, idea papers, original research, and review articles that focus on the leading edge, novel ideas for improving, modernizing, and advancing pharmacy practice, education, and policy. INNOVATIONS in pharmacy is an academic, peer reviewed, open-access journal. Sponsored by U of MN College of Pharmacy Inspiring Inquiry and Improvement in Pharmacy Practice, Education, and Policy. A quarterly publication featuring case studies, clinical experiences, commentaries, idea papers, original research, review articles, and student projects that focus on leading edge, novel ideas for improving, modernizing, and advancing pharmacy practice, education, and policy. INNOVATIONS in pharmacy.
- 5 November 2024
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 21 (2) , 85-93
A deep neural network model for classifying pharmacy practice publications into research domains
- 5 November 2024
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 21 (2) , 85-93
A deep neural network model for classifying pharmacy practice publications into research domains
- Open Access
- 18 July 2023
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 6 (11) , 1191-1202
The impact of the COVID‐19 pandemic on school‐level scholarly outcomes and research focus of pharmacy practice faculty
Introduction: The effects of the coronavirus disease 2019 (COVID‐19) pandemic on scholarly outcomes and research focus of schools of pharmacy (SOPs) have not been studied.Objectives: To determine how objective measures of scholarly outcomes and research focus changed in pharmacy practice among SOPs, within geographic regions, during the COVID‐19 pandemic.Methods: SOPs were included if they appeared on the National Institutes of Health (NIH) funding list in all four index years (2018–2019: pre‐pandemic and 2020–2021: pandemic) and ranked among the top 50 at least once between 2018 and 2021. Names of pharmacy practice faculty were obtained from the American Association of Colleges of Pharmacy (AACP) directory. The publication records of each SOP were obtained from Scopus. Scholarly outcome measures were scholarly activity ratio (SAR; proportion of faculty members who published) and scholarly output (SO; number of documents published). Data was analyzed using Microsoft Excel, VOSviewer®, and Python. Statistical analysis was done in R using a mixed effects model, with the pandemic and geographic regions as fixed effects, and SOPs as the random effect.Results: Fifty‐five SOPs and 1343 faculty members were included. Neither the pandemic nor geographic region had significant effects on SAR. However, both variables had significant effects on SO, as demonstrated by an increase in the Midwest during the pandemic (p < 0.05). Documents published increased from 2755 to 3001 during the pandemic. This 8.9% increase was lower than a historical average biennial increase of 24.9%. COVID‐19 was the top new research topic, constituting 56.5% of the increase over the pre‐pandemic period. Of these COVID‐19 publications, 20.9% were education‐related.Conclusion: Pharmacy practice faculty engaged in COVID‐19 research that focused predominantly on education. Scholarly‐active faculty were resilient, but their output was lower than expected based on historical trends. These results support the need to adjust tenure and promotion benchmarks and/or timelines related to scholarly output, especially for tenure‐track faculty with probationary periods spanning these pandemic years.
- 18 July 2023
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 6 (11) , 1191-1202
Open AccessThe impact of the COVID‐19 pandemic on school‐level scholarly outcomes and research focus of pharmacy practice faculty
Introduction: The effects of the coronavirus disease 2019 (COVID‐19) pandemic on scholarly outcomes and research focus of schools of pharmacy (SOPs) have not been studied.Objectives: To determine how objective measures of scholarly outcomes and research focus changed in pharmacy practice among SOPs, within geographic regions, during the COVID‐19 pandemic.Methods: SOPs were included if they appeared on the National Institutes of Health (NIH) funding list in all four index years (2018–2019: pre‐pandemic and 2020–2021: pandemic) and ranked among the top 50 at least once between 2018 and 2021. Names of pharmacy practice faculty were obtained from the American Association of Colleges of Pharmacy (AACP) directory. The publication records of each SOP were obtained from Scopus. Scholarly outcome measures were scholarly activity ratio (SAR; proportion of faculty members who published) and scholarly output (SO; number of documents published). Data was analyzed using Microsoft Excel, VOSviewer®, and Python. Statistical analysis was done in R using a mixed effects model, with the pandemic and geographic regions as fixed effects, and SOPs as the random effect.Results: Fifty‐five SOPs and 1343 faculty members were included. Neither the pandemic nor geographic region had significant effects on SAR. However, both variables had significant effects on SO, as demonstrated by an increase in the Midwest during the pandemic (p < 0.05). Documents published increased from 2755 to 3001 during the pandemic. This 8.9% increase was lower than a historical average biennial increase of 24.9%. COVID‐19 was the top new research topic, constituting 56.5% of the increase over the pre‐pandemic period. Of these COVID‐19 publications, 20.9% were education‐related.Conclusion: Pharmacy practice faculty engaged in COVID‐19 research that focused predominantly on education. Scholarly‐active faculty were resilient, but their output was lower than expected based on historical trends. These results support the need to adjust tenure and promotion benchmarks and/or timelines related to scholarly output, especially for tenure‐track faculty with probationary periods spanning these pandemic years.
- 8 November 2022
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 19 (3) , 477-485
Trends in authorship characteristics and collaboration in pharmacy practice publications: 2011–2020
- 8 November 2022
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 19 (3) , 477-485
Trends in authorship characteristics and collaboration in pharmacy practice publications: 2011–2020
- 3 May 2022
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 36 (4) , 941-952
Stigma by Association: To what Extent is the Attitude Toward Naloxone Affected by the Stigma of Opioid Use Disorder?
The United States opioid epidemic is fueled by illicit opioid abuse and prescription opioid misuse and abuse. Consequently, cases of opioid use disorder (OUD, opioid addiction), opioid overdose, and related deaths have increased since the year 2000. Naloxone is an opioid antagonist that rapidly reverses opioid intoxication to prevent death from overdose. It is one of the major risk mitigation strategies recommended in the 2016 Centers for Disease Control and Prevention Guideline for Prescribing Opioids for Chronic Pain. However, despite the exponential increase in dispensing and distribution of naloxone, opioid overdose and related deaths have continued to increase; suggesting that the increased naloxone supply still lags the need. This discordance is attributed at least in part to the negative attitude toward naloxone, which is based on the belief that naloxone is only meant for “addicts” and “abusers” (OUD patients). This negative attitude or so-called naloxone stigma is therefore considered a major barrier for naloxone distribution and consequently, overdose-death prevention efforts. This article presents evidence that challenges common assertions about OUD stigma being the sole and direct driving force behind naloxone stigma, and the purported magnitude of the barrier that naloxone stigma constitutes for naloxone distribution programs among the stakeholders (patients, pharmacists, and prescribers). The case was then made to operationalize and quantify the construct among the stakeholders to determine the extent to which OUD stigma drives naloxone stigma, and the relative impact of naloxone stigma as a barrier for naloxone distribution efforts.
- 3 May 2022
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 36 (4) , 941-952
Stigma by Association: To what Extent is the Attitude Toward Naloxone Affected by the Stigma of Opioid Use Disorder?
The United States opioid epidemic is fueled by illicit opioid abuse and prescription opioid misuse and abuse. Consequently, cases of opioid use disorder (OUD, opioid addiction), opioid overdose, and related deaths have increased since the year 2000. Naloxone is an opioid antagonist that rapidly reverses opioid intoxication to prevent death from overdose. It is one of the major risk mitigation strategies recommended in the 2016 Centers for Disease Control and Prevention Guideline for Prescribing Opioids for Chronic Pain. However, despite the exponential increase in dispensing and distribution of naloxone, opioid overdose and related deaths have continued to increase; suggesting that the increased naloxone supply still lags the need. This discordance is attributed at least in part to the negative attitude toward naloxone, which is based on the belief that naloxone is only meant for “addicts” and “abusers” (OUD patients). This negative attitude or so-called naloxone stigma is therefore considered a major barrier for naloxone distribution and consequently, overdose-death prevention efforts. This article presents evidence that challenges common assertions about OUD stigma being the sole and direct driving force behind naloxone stigma, and the purported magnitude of the barrier that naloxone stigma constitutes for naloxone distribution programs among the stakeholders (patients, pharmacists, and prescribers). The case was then made to operationalize and quantify the construct among the stakeholders to determine the extent to which OUD stigma drives naloxone stigma, and the relative impact of naloxone stigma as a barrier for naloxone distribution efforts.